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The Raf-MEK-ERK signalling pathway controls fundamental cellular processes including proliferation, differentiation and survival. It
remains enigmatic how this pathway can reliably convert a myriad of extracellular stimuli in specific biological responses. Recent
results have shown that the Raf family isoforms A-Raf, B-Raf and Raf-1 have different physiological functions. Here we review how Raf
isozyme diversity contributes to the specification of functional diversity, in particular regarding the role of Raf isozymes in cancer.
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Raf first came to the fore as a retroviral oncogene, v-Raf or v-Mil,
which could induce tumours in mice and chickens, respectively.
Raf-1, the cognate proto-oncogene, is widely expressed and
became the most intensely studied Raf family member. The other
two family members, A-Raf and B-Raf, feature a more restricted
expression. A-Raf is mainly expressed in urogenital tissues and B-
Raf expression is highest in neuronal tissues, testis and
haematopoetic cells, although recent experiments suggest that
the expression of A-Raf and B-Raf at low levels is much more
widely spread (reviewed by Kolch, 2000).
Interest in Raf proteins surged upon identification of their role
as direct effectors of Ras. Ras has suffered oncogenic mutations in
nearly 30% of all human cancers. All the three Raf family members
share the biochemical properties of binding to Ras and to
phosphorylate and activate MEK (reviewed by Kolch, 2000; Avruch
et al, 2001). Currently, MEK is the only generally acknowledged
substrate of Raf kinases. MEK phosphorylates and activates ERK.
While Raf and MEK appear restricted to only one class of
substrates, ERK musters more than 70 substrates including nuclear
transcription factors (Lewis et al, 1998). This led to the perception
of a linear pathway where Ras funnels a great variety of
extracellular cues into a three-tiered kinase module, Raf-MEK-
ERK, which relies on ERK to dispense the signal to various
substrates. An obvious problem with this view is how to rationalise
that this pathway controls many and diverse fundamental cellular
functions including proliferation, differentiation, transformation
and apoptosis.
The specificity of biological responses can be encoded in a
number of ways. Specificity can be achieved by compartmentalisa-
tion, where the accessibility to upstream activators and down-
stream substrates is regulated by subcellular localisation. The
response can also depend on the cellular context, such as the
expression of other proteins and activity of other pathways. This
requires points of crosstalk where these contextual signals are
integrated. In such a scenario, the exact kinetics and duration of
ERK signalling will play a major role. Such fine tuning can be
adjusted by the differential response of upstream activators to
external cues. There may also be yet unrecognised branchpoints
that distribute signals into other downstream pathways. These
mechanisms are not mutually exclusive, and recent discoveries
support all of these possibilities. In this review, we will briefly
discuss this evidence.
RAF GENE KNOCKOUTS
The most convincing case for isozyme-specific functions of the
three Raf family genes was made by knockout studies in mice. The
ablation of the A-raf gene (Pritchard et al, 1996) results in
neurological defects. In an inbred background, mice die 7–21 days
post partum from megacolon caused by a defect in visceral
neurons that control bowel contractions. In an outbred back-
ground, A-raf
/ mice survive to adulthood, but still feature
defects in proprioception and abnormal movements. This
phenotype resembles Neurotrophin-3 (NT-3)-deficient mice
(Kirstein and Farinas, 2002). NT-3 also promotes the survival of
visceral neurons. These observations would place A-Raf in a NT-3-
mediated neuronal survival pathway. The lack of A-Raf did not
affect the regulation of ERK in mouse embryonic fibroblasts
(MEFs) or the transformation of these cells, suggesting that these
functions are compensated for by the other Raf family members
(Mercer et al, 2002).
Raf-1-deficient mice die in midgestation, due to widespread
apoptosis throughout the embryo (Huser et al, 2001; Mikula et al,
2001). The penetrance of the phenotype was more severe in inbred
than in outbred backgrounds. Surprisingly, ERK activation by
growth factors was not compromised in Raf-1
/ MEFs, pre-
sumably due to compensation by B-Raf. Even more surprisingly, a
Raf-1 mutant that is refractory to growth factor stimulation could
rescue the knockout phenotype, resulting in viable and apparently
Received 19 August 2003; revised 14 October 2003; accepted 15
October 2003
*Correspondence: Dr E O’Neill; E-mail: e.oneill@beatson.gla.ac.uk
British Journal of Cancer (2004) 90, 283–288
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.comnormal mice (Huser et al, 2001). Overall, the Raf-1
/ phenotype
resembles K-Ras
/ as well as Fas-ligand transgenic mice. These
observations suggest that Raf-1 is a main effector of K-Ras, and
that a major task of Raf-1 is to restrain the proapoptotic function
of Fas signalling. Indeed, Raf-1 MEFs exhibited increased
sensitivity to Fas-induced apoptosis (Huser et al, 2001; Mikula
et al, 2001). Much needed detailed mechanistic investigations are
just beginning. The cause of the anaemia in Raf-1
/ animals was
traced back to the elevation of caspase-1 activity that accelerated
erythroid differentiation to a point where erythroid progenitor
cells became depleted (Kolbus et al, 2002). All these observations
point to effectors distinct from MEK and ERK mediating Raf-1’s
antiapoptotic role.
B-raf
/ mice (Wojnowski et al, 1997) provided the first genetic
evidence for a role of a Raf isoform in the regulation of apoptosis.
These mice die in midgestation, due to haemorrhage caused by
massive apoptosis of endothelial cells. However, the interpretation
of these data is confounded by the uncertainty whether the
knockout strategy has abolished the expression of all the B-raf
splice forms. Nevertheless, the very different phenotypes of
the Raf knockout mice indicate that Raf isoforms have different
biological functions. B-Raf emerges as the main regulator of
the MEK-ERK pathway, while Raf-1 and A-Raf seem to provide
ERK-independent apoptosis protection in different tissues.
This conclusion is likely too simplistic, but can serve as a
useful working hypothesis for the dissection of Raf isoform
function.
An elegant biochemical study of the contribution of Raf-1 and B-
Raf to B-cell receptor (BCR) signalling showed that Raf-1 and B-
Raf are activated with different kinetics and cooperate in many
downstream responses (Brummer et al, 2002). DT40 B-cells were
engineered so that either gene could be deleted individually, or
both together. Raf-1 was dispensable for BCR-mediated ERK
activation, while the ablation of B-Raf caused a reduced and
shortened activity of ERK. The Raf-1/B-raf double knockout
resulted in an almost complete loss of ERK activation and severely
reduced expression of the downstream transcriptional targets c-
Fos and Egr-1. Only the activation of nuclear factor of activated T
cells, NFAT, was mainly dependent on B-Raf. The molecular basis
for the cooperation between Raf-1 and B-Raf is not yet understood.
It could rely on complementation at the level of downstream
substrates, including specific differences in activation kinetics. It
also could be related to the ability of Raf-1 to heterodimerise with
B-Raf. The heterodimer, conceivably, could have different signal-
ling properties than either individual protein.
RAF ISOFORM REGULATION AND FUNCTION
All the three Raf isoforms contain a Ras-binding site (RBD) in the
regulatory domain at the N-terminus, and can consequently be
activated by Ras GTPases. The RBD selectively binds to activated
GTP-loaded Ras, but the effects are different. Ras binding does not
activate Raf-1 directly, but seems to serve to translocate Raf-1 from
the cytosol to the membrane, where subsequent activation events
occur (Dhillon and Kolch, 2002). These comprise a complex series
of events starting with the dephosphorylation of S259, which
allows phosphorylation of S338 and possibly Y341 as well as two
sites in the activation loop. These modifications work together not
only to determine the quantity of the signalling output, but also
maybe even the quality. Raf-1 S259 mutant can activate ERK to a
similar extent as the v-Raf oncogene, yet fails to transform the
cells, suggesting that the quality of the downstream signal is
different depending on the upstream mode of activation (Dhillon
et al, 2003). Rather little is known about the regulation of A-Raf,
but it seems to be regulated in a similar way as Raf-1 yet binds to
Ras more weakly and also is a weaker MEK kinase (Marais et al,
1997).
In contrast, B-Raf is activated directly by Ras binding. B-Raf also
features a phosphomimetic aspartate in place of the residue
corresponding to Y341, and is constitutively phosphorylated at the
S338 equivalent (Mason et al, 1999). Thus, B-Raf appears to have
shortcircuited several of the events required for the activation of
Raf-1. This is consistent with B-Raf possessing a much higher
specific activity towards MEK than Raf-1. This could explain why
B-raf can fully compensate for the loss of Raf-1 or A-Raf in the
knockout cells pertaining to the regulation of ERK.
In addition, B-Raf can be activated by Rap1 (York et al, 1998), a
Ras-related protein, which was originally described as a suppressor
of Ras transformation. This inhibitory function seems to be due to
the ability of Rap1 to sequester Raf-1 in inactive complexes. As this
requires Rap1 overexpression, it is unclear whether this function of
Rap1 is physiological. Rap1 is activated by numerous growth
factors and appears to be a signal transducer in its own right (Bos
et al, 2001). Again, it has been disputed whether B-Raf is a
physiological Rap1 effector (Bos et al, 2001), but at least under
certain conditions it can promote PC12 cell differentiation by
activating B-Raf. The higher activity of B-Raf ensures the sustained
activation of ERK that is required for neuronal differentiation of
PC12 cells. However, there is also differential regulation down-
stream through crosstalk with the cAMP signalling system. The
cAMP-dependent protein kinase PKA phosphorylates and inhibits
Raf-1. In contrast, cAMP induces the activation of B-Raf by
activation of Rap1 (York et al, 1998). Thus, cAMP should interfere
with ERK activation in cells where only Raf-1 is expressed, but
promote ERK activation in cells where B-Raf is coexpressed.
Switching from one Raf isoform with low MEK kinase activity to
another with high activity could serve to fine-tune the activation
dynamics of ERK, in order to determine a specific biological
response (Figure 1). A recent study has shown how ERK activation
kinetics can be converted into differential responses (Murphy et al,
2002). A transient activation of ERK will induce the expression of
Fos by phosphorylating the Elk and Sap transcription factors. As
the Fos protein is very unstable, the impact on a transcriptional
response is limited. However, sustained ERK signalling results in
the activation of Rsk, which phosphorylates and stabilises Fos,
producing a robust transcriptional activation.
RAF ISOFORMS IN CANCER
Raf-1 is the cellular proto-oncogene homologue of v-Raf. v-Raf
corresponds to the Raf-1 kinase domain. Indeed, the deletion of
the regulatory domain converts Raf-1 into an oncogene, termed
BXB (Heidecker et al, 1990). However, genetic alterations of Raf-1
in human tumours have not been found. Lung tumour cell lines
often overexpress Raf-1, and a transgenic mouse model has been
developed where Raf gene expression is targeted to the lungs by
use of a tissue-specific promoter (Rapp et al, 2003). BXB
overexpression rapidly induced numerous well-differentiated,
noninvasive adenomas. Surprisingly, the overexpression of Raf-1,
which is nontransforming in cell culture models, also resulted in
the formation of adenomas with the same histological phenotype.
These tumours were fewer and delayed, and, in contrast to BXB,
induced adenomas did not feature elevated ERK activity. These
findings suggest that Raf-1 contributes to different aspects of
malignancy, including ERK-independent processes and those
which escape in vitro experimentation. Crossing the BXB
transgenic mice with bcl-2 knockout mice did not change the
tumour phenotype, but retarded tumour development mainly due
to an increase in the rate of apoptosis. In contrast, the concomitant
loss of p53 accelerated tumour growth and also changed the
histological composition from cuboid cells to papillary tumours
with large columnar epithelial cells. Despite occasional bronchiolar
invasion, no metastasis was observed. These phenotypes resemble
human atypical adenomatous lung hyperplasia, which may be the
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Thus, studies to validate the role of Raf-1 in human lung cancer are
eagerly awaited. In particular, it may be interesting to examine the
role of B-Raf.
B-Raf is mutated in 66% of melanomas and a smaller number of
other prevalent cancers such as colon tumours. While the
activation of Raf-1 requires a complex series of events, the
activation of B-Raf is much simpler to achieve, explaining why B-
Raf is a preferred target for mutational activation in human
cancers (Mercer and Pritchard, 2003). The main mutation is
V599E, which introduces a negative charge into the activation
loop. This phosphomimetic mutation suffices to deregulate B-Raf
activity and convert it into an oncogene (Davies et al, 2002). In the
meantime, a flurry of studies has established that B-Raf is indeed
mutated in a great variety of cancers albeit, with the exception of
thyroid carcinoma, B-Raf mutation has a rather low incidence
(Mercer and Pritchard, 2003). Most of these tumour types are
known to have Ras mutations, but interestingly, Ras and B-Raf
mutations usually do not coincide in the same tumour. This
observation provides strong genetic evidence that B-Raf is a crucial
effector for Ras-mediated tumourigenesis; however, the exact
molecular mechanism is still obscure. Besides the prevalent V599E
mutation, which enhances kinase activity, there are three other
classes of mutations whose functional consequences are less clear
(Mercer and Pritchard, 2003). One class affects the Akt phosphor-
ylation sites in B-Raf, which have been implicated in the inhibition
of B-raf kinase activity. Obviously, these mutations would only
activate B-raf in cells where its activity is restrained through Akt.
Another class of mutations that leads to modest activation is found
in the ATP-binding glycine-rich loop. Yet another type alters the
conserved DFG motif at the base of the activation loop. Such
mutations usually incapacitate the kinase activity. These mutations
are rare, but challenge the view that the oncogenic conversion of B-
Raf is only due to the chronic hyperstimulation of the MEK-ERK
pathway. A plausible explanation is that B-Raf has a role that is
independent of its kinase activity, for instance, as a scaffolding
protein or as a dominant-negative mutant, which sequesters
proteins that prevent transformation.
DIVERSIFICATION AT THE SUBSTRATE LEVEL
B-Raf appears to be the main activator of the MEK-ERK pathway
(Huser et al, 2001; Mikula et al, 2001), and the simplicity of B-Raf
activation rationalises why B-raf is a preferred target for oncogenic
mutation. However, it also leaves a puzzle. Why does nature go to
such great lengths to regulate the comparably poor kinase activity
of Raf-1 in this very complicated manner? A provocative
possibility is that MEK is not the main relevant substrate of Raf-
1, or that these post-translational modifications serve as docking
platforms to assemble functionally different Raf-1 complexes.
The interpretation of yet unknown Raf-1 substrates is in line
with the phenotype of the Raf-1
/ mice which succumb to
deregulated apoptosis despite an apparently normal regulation of
ERK. There is also a growing body of circumstantial evidence that
not all functions of Raf-1 are dependent on its ability to activate
MEK (Hindley and Kolch, 2002). Obviously, the existence of Raf
isoform-specific substrates would neatly explain isoform diversity.
A number of alternative Raf-1 substrates have been described, but
none has been unequivocally validated yet. One presumably Raf
isoform-specific substrate is the retinoblastoma protein (Rb). Rb
phosphorylation is required to traverse the G1–S-phase boundary
of the cell cycle. Although Rb is classically viewed as a target for
cyclin D- and E-dependent cell cycle kinases, other kinases may
contribute to its inactivation. Raf-1 has been reported to promote
the inactivation of Rb by directly phosphorylating it. Rb
phosphorylation was dependent on binding to the 25 N-terminal
amino acids of Raf-1. This stretch is unique and hence Rb should
be a Raf-1 isoform-specific target (Wang et al, 1998).
However, there is also the possibility that Raf isoforms convey
specificity through conveying differential activation kinetics on
their common substrate MEK. The PC12 cell paradigm has been
discussed above. Studies in IL-3-dependent haematopoetic cell
lines showed that the A-Raf kinase domain abrogates growth factor
dependence more efficiently than the Raf-1 or B-Raf kinase
domains. However, in all cases, this process was MEK dependent
(Hoyle et al, 2000).
Yet another level of specificity could be achieved through the
differential activation of MEK and ERK isoforms. Both MEK and
ERK feature two isoforms in mammalian cells. A common
assumption is that they are functionally equivalent. However,
their evolutionary conservation suggests that they exert nonre-
dundant functions. This is proven by the phenotype of MEK and
ERK knockout mice. Knocking out MEK-1 results in an embryonic
lethal phenotype which is similar, but not identical to the Raf-1
knockout (Giroux et al, 1999). This confirms that MEK-1 is a
physiologically relevant target of Raf-1, but also points to a more
complicated scenario where signals diversify from MEK isoforms.
Indeed, in Hela cells, A-Raf selectively activated MEK-1 in
response to EGF, whereas Raf-1 activated both MEK-1 and MEK-
2 (Wu et al, 1996). In a similar vein, the ablation of ERK-1 does not
compromise viability and causes rather subtle changes in the
functions of T-cells and memory. In contrast, knocking out ERK-2
is embryonic lethal (Saba-El-Leil et al, 2003). At present, the
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Figure 1 PC12 cell model of neuronal differentiation. This model shows how a biological response is specified by the kinetics and duration of ERK activity,
which is achieved through the combinatorial integration of activating different Raf isoforms and crosstalk with the cAMP signalling system. PC12 cells
differentiate in response to the nerve growth factor (NGF), but proliferate in response to the epidermal growth factor (EGF). Both growth factors utilise the
Raf/MEK/ERK pathway. The biological response is determined by the duration of ERK signalling. Sustained ERK activation results in neuronal differentiation.
The sustenance of ERK activity is caused by the B-Raf isoform, which is activated preferentially by NGF. Differentiation is further enhanced by activation of
cAMP signalling, which inhibits Raf-1, but promotes B-Raf activity.
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MEK and ERK isoforms are coregulated. A potential answer could
be provided by differential subcellular compartmentalisation and
complex formation.
SIGNAL DIVERSIFICATION THROUGH SCAFFOLDING
PROTEINS AND SUBCELLULAR LOCALISATION
Signalling through this pathway is regulated by protein interac-
tions that serve to connect activators with effectors, as well as
target them to different subcellular localisations (Kolch, 2000). The
binding of Raf kinases to Ras translocates Raf to the membrane
compartment, where activation ensues. The artificial targeting to
the plasma membrane suffices to partially activate Raf-1. Ha-Ras is
not only activated at the cell membrane, but also on endomem-
branes, resulting in a differential interaction with downstream
targets. Tethering Ha-Ras to the Golgi preferentially activated JNK,
while Ha-Ras targeted to the endoplasmic reticulum stimulated
ERK and Akt activities (Chiu et al, 2002). This observation
suggests that the quality of the downstream signal is determined by
the subcellular localisation of Ras, which by implication regulates
the interaction with downstream effectors.
This theme is also encountered further downstream in the
pathway. The scaffolding protein KSR constitutively binds to MEK.
In response to mitogenic stimulation, the KSR/MEK complex is
recruited from the cytosol to the cell membrane, where it can now
interact with activated Raf-1 and ERK to facilitate the signal flux
through the kinase module Raf-MEK-ERK (Muller et al, 2001).
Gene knockout experiments in the worm C. elegans, which like
mammals has two KSR genes, has revealed overlapping as well as
some specific functions for the two KSR genes. However, when
both genes were removed, ERK activation was severely compro-
mised and the phenotype was similar to disabling the let-60 Ras
gene (Ohmachi et al, 2002). Knocking out KSR1 in mice did not
result in any gross abnormalities, although ERK activation in
response to growth factors was modestly attenuated and the T-cell
response to antigen was impeded. Remarkably, however, the
KSR1
/ mice were significantly less susceptible to developing
mammary tumours when crossed to a transgenic tumour-prone
strain (Nguyen et al, 2002). This opens a new opportunity for
therapeutic intervention. Interfering with KSR expression or
function would be expected to impede tumour growth, but leave
normal cells unscathed.
Another example is MP-1, a small scaffold that ties MEK and
ERK together. MP-1 also binds to p14, an endosomal protein,
which targets the MEK/ERK/MP-1 signalling complex to late
endosomes. The downregulation of p14 or MP-1 protein levels
diminished ERK activation and the induction of Elk-1-dependent
reporter gene expression (Teis et al, 2002). These results suggest
that the Raf/MEK/ERK pathway is organised in spatially distinct
signalling complexes. It remains to be shown whether this
correlates with functional diversity. An attractive possibility is
that the spatial segregation could determine selective interactions
with upstream activators and downstream effectors (Figure 2).
For instance, a fraction of Raf-1 was found at the mitochondria
and the artificial targeting of activated Raf-1 to mitochondria
inhibited apoptosis. Curiously, mitochondrial Raf-1 did not
activate the MEK-ERK pathway, but rather phosphorylated and
inactivated BAD, a proapoptotic protein (Wang et al, 1996).
Unfortunately, BAD was not confirmed as a direct Raf-1 substrate,
and the search for the physiological substrate of mitochondrial
Raf-1 is still ongoing. Interestingly, A-Raf was also detected in rat
liver mitochondria. In contrast to Raf-1, which is loosely and
peripherally associated, A-raf appears to be a true mitochondrial
protein. It interacts with the putative mitochondrial import
proteins hTOM and hTIM, and is found in the intermembrane
space and the matrix (Yuryev et al, 2000). The function of A-Raf at
the mitochondria is unknown. However, given that A-Raf is a very
poor MEK kinase, an alternative mitochondrial substrate seems
plausible.
These results also demonstrate that the identification of
interaction partners is a viable strategy to unravel new functional
connections. A recent systematic study used the N-terminal
regulatory domains of Raf-1 and A-Raf, respectively, as baits in
an exhaustive yeast two-hybrid screen (Yuryev and Wennogle,
2003). In total, 20 different proteins were identified, including
several novel interaction partners. Half of these proteins exhibited
isoform selectivity, six proteins binding to A-raf and four to Raf-1.
Even more surprisingly, this selectivity was encoded by the
cysteine-rich zinc-binding domain (CRD). This domain is essential
for activation by Ras, although it is not the primary Ras-binding
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Figure 2 Different signalling complexes and subcellular compartmentalisation can generate diverse cellular responses. See text for details.
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hub for isoform selective protein interactions. They also predict
the existence of a great number of distinct Raf signalling
complexes, as the small size of the CRD makes simultaneous
interactions unlikely. Clearly, a future challenge will be to unravel
the composition of multiprotein signalling complexes in situ and
characterise the dynamics of the interactions. The recent progress
in proteomics and the improvement of imaging techniques for
monitoring protein interactions at subcellular resolution and in
real time will allow us to tackle these questions.
CONCLUSION
The number of our genes is too small to account for the complexity
of biological functions. Thus, the cell employs the same proteins in
different contexts and imposes specificity through combinatorial
mechanisms. Using the Raf/MEK/ERK signalling pathway as
paradigm, we have highlighted some of these mechanisms
including differential protein interactions, subcellular compart-
mentalisation, different modes of activation, and differential
targeting of downstream effectors. A recent study elegantly
demonstrates how the cell orchestrates this repertoire of mechan-
isms (Alavi et al, 2003). In endothelial cells, vascular endothelial
growth factor (VEGF) protects from apoptosis caused by serum
starvation and DNA-damaging drugs, whereas basic fibroblast
growth factor (bFGF) prevents the apoptosis induced by death
receptor stimulation. Both pathways employ Raf-1, yet use
different modes of activation and different downstream effectors.
bFGF protection is MEK independent and involves the activation
of Raf-1 by phosphorylation of S338 and Raf-1 translocation to
mitochondria. In contrast, VEGF-mediated survival is MEK
dependent, does not translocate Raf-1 to mitochondria, and uses
phosphorylation of Y341 to activate Raf-1. This example shows
how the mode of activation could specify downstream signalling
through differential subcellular localisation. Unveiling this combi-
natorial complexity will be the next great challenge for modern
biology.
This task will also have enormous repercussions on drug
development. Potent Raf and MEK inhibitors have been tested in
clinical trials. In particular, the Raf inhibitor BAY 43-9006 was well
tolerated, showing good efficacy as a single agent and in
combination therapies (Hotte and Hirte, 2002). However, the
realisation that one protein can have different functions in
different cellular contexts will warrant new strategies for drug
design. Target validation will rely on understanding these
networks, which will only be possible at a systems biology level
requiring quantitative biology combined with massive in silico
simulation. We also will need to develop appropriate screens for
new categories of targets, which may include protein interactions
and subcellular distribution. Future drug development will rely on
vigorous basic research in these areas and interdisciplinary
collaboration to translate the findings into applications.
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